Written question asked by Alex Cunningham (Labour) on Friday, 13 May 2022, in the House of Commons. It was due for an answer on Wednesday, 18 May 2022 (named day). It was answered by Maggie Throup (Conservative) on Tuesday, 7 June 2022 on behalf of the Department of Health and Social Care.
Tixagevimab/cilgavimab
- Question
-
To ask the Secretary of State for Health and Social Care, what plans his Department has to make Evusheld available to immunocompromised people.
- Original answer
-
Evusheld has been granted conditional marketing approval by the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March 2022. However, the MHRA highlighted uncertainty over the appropriate dose needed for protection against the Omicron variant. Understanding the efficacy of Evusheld is necessary prior to any procurement or deployment.
The UK Health Security Agency is currently undertaking further testing on the treatment’s effectiveness against the Omicron variant. This will inform any decisions on the potential procurement of this treatment.
-
It has since been corrected.
Secondary information
- Type
- Written question
- Reference
- 1507
- Session
- 2022-23
- Related items
-
Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Commons
-
Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Lords
- Notes
- Information corrected on 17 April at 731 c10-2WS
- Subjects
- Immunosuppression Tixagevimab/cilgavimab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-05-24 09:59:45 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/1507
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/1507
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/1507